Health Evaluation of Mushrooms withVitamin D2

Healthy Clinical Trial

Official title:

Health Evaluation of Mushrooms withVitamin D2

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05716698
• Other study ID #: N202111054
• Status: Completed
• Phase: N/A
• Start date: April 15, 2022
• Est. completion date: June 1, 2022

Study information

• Verified date: February 2022
• Source: Taipei Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although Taiwan has plenty of sunshine, the intake of vitamin D and the concentration of 25(OH)D in the blood are low. Ingestion of mushrooms and extracts rich in D2 can increase the nutritional source of vitamin D. The purpose of this study is to evaluate the intake of D2 mushrooms and extracts in humans to achieve the effective concentration of 25(OH)D in the serum and recommendations for health improvement.

Description:

The subjects were divided into 3 groups: no mushroom intervention, intervention with D2 10ug Pleurotus citrinopileatus after bio-optics optimization (low dose group) or intervention with D2 100ug Pleurotus citrinopileatus after bio-optics optimization (high dose group). The low-dose group took D2 10ug per day, and the high-dose group received D2 100ug per day for a total of 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Healthy human

Exclusion Criteria:

1. Any acute disease, such as infection, stroke, myocardial infarction or major surgery within three months, upper or lower gastrointestinal bleeding, blood pressure, and poor blood sugar control will be excluded.

2. Chronic diseases, such as malignant tumors, infection with human immunodeficiency virus (HIV) and related diseases, liver cirrhosis, or those with liver function exceeding 3 times the normal value (more than 120 IU/L), renal function (Cr) more than 2.5 mg /dl, chronic anemia (Hb <9 g/dl), metabolic diseases except diabetes (such as thyroid/parathyroid dysfunction), and those who have undergone abdominal surgery to cause intestinal sticking are excluded.

3. Women who are pregnant or breastfeeding will be excluded.

4. Those who use steroids, supplements with vitamin D-containing dietary supplements and hormones will be excluded.

5. Those with blood 25(OH)D concentration > 30 ng/ml will be excluded.

6. Those who are unwilling to fill out the consent form and refuse the questionnaire survey.

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• Pleurotus citrinopileatus after bio-optics (10 ug group)
The participants took D2 10ug per day for a total of 4 weeks.
• Pleurotus citrinopileatus after bio-optics (100 ug group)
The participants took D2 100ug per day for a total of 4 weeks.

Locations

Country	Name	City	State
Taiwan	Taipei Medical University	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in 25OHD at week 4	The participants' blood was taken to analyze the concentration of 25OHD to compare the changes between baseline and 4 weeks later. 25OHD concentration standard is: 25OHD < 20 ng/ml: deficiency 20 ng/ml < 25OHD < 30 ng/ml: Insufficiency 25OHD > 30 ng/ml: Normal	Baseline and week 4